Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $77.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 15.42% to $77.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.5 million through Dec 2025, down 15.42% year-over-year, with the annual reading at $77.5 million for FY2025, 15.42% down from the prior year.
  • Other Non-Current Liabilities hit $77.5 million in Q4 2025 for Axsome Therapeutics, down from $89.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 to a low of $27.4 million in Q3 2022.
  • Historically, Other Non-Current Liabilities has averaged $60.5 million across 4 years, with a median of $70.0 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 163.01% in 2024 and later dropped 15.42% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $31.1 million in 2022, then soared by 135.69% to $73.3 million in 2023, then rose by 25.08% to $91.7 million in 2024, then decreased by 15.42% to $77.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AXSM at $77.5 million in Q4 2025, $89.9 million in Q3 2025, and $79.7 million in Q2 2025.